UCB announces positive data in myasthenia gravis with ziluco

/PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive topline results from the RAISE (NCT04115293) triali evaluating its...

Related Keywords

Japan , United States , Denmark , Massachusetts , Belgium , China , Boston , Spain , Brussels , Bruxelles Capitale , Spanish , Mjamesf Howard , Jim Baxter , Iris Loew Friedrich , Antje Witte , Seanm Healey , Howard Jf Jr , Natalie Jones , Raquel Pardo , Brand Communications , Twitter , Spanish Myasthenia Association , Rare Disease Communications , European Union , Myasthenia Gravis Foundation Of America , Corporate Communications , University Of North Carolina School Medicine , Lancet Reg Health West Pac , Myasthenia Gravis Activities , Daily Living Profile , Quantitative Myasthenia Gravis , Myasthenia Gravis Composite , Distinguished Professor , Neuromuscular Disease , Neuromuscular Disorders Section , North Carolina School , Chief Medical Officer , Generalized Myasthenia Gravis , Subjects With Generalized Myasthenia Gravis , Daily Living , Myasthenia Gravis Quality , Massachusetts General Hospital , Rare Diseases , Euronext Brussels , Disease Communications , Reg Health West , Practice Myasthenia , Myasthenia Gravis Foundation , Clinical Overview , Clinical Trials , Accessed November , Test Efficacy , Accessed February , Ucb , Nc ,